Journal of Cataract & Refractive Surgery
Volume 35, Issue 12 , Pages 2121-2126, December 2009

Glistenings in a large series of hydrophobic acrylic intraocular lenses

Presented in part at the XXVI Congress of the European Society of Cataract & Refractive Surgeons, Berlin, Germany, September 2008.

  • Joseph Colin, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Joseph Colin, MD, Service d'Ophtalmologie, Hôpital Pellegrin, CHU de Bordeaux, Place Amélie Raba Léon, 33 000 Bordeaux, France.
    • ,
  • Isabelle Orignac, MD
    • ,
  • David Touboul, MD

From Service d'Ophtalmologie, Hôpital Pellegrin, Centre Hospitalier et Universitaire de Bordeaux (Colin, Orignac), and Centre de Référence Nationale du Keratĉone citu de Bordeaux (Touboul), Bordeaux, France

Received 12 February 2009; received in revised form 12 June 2009; accepted 16 June 2009.

Purpose

To evaluate the incidence and severity of glistenings in hydrophobic acrylic intraocular lenses (IOLs) and assess the potential correlation between glistenings and clinical and demographic factors.

Setting

Service d'Ophtalmologie, Centre Hospitalier et Universitaire Bordeaux, Bordeaux, France.

Methods

Eligible patients received an AcrySof IOL between September 2000 and December 2007 and had a routine ophthalmic visit between January 2007 and March 2008. The incidence and severity of glistenings were graded subjectively and analyzed in relation to patient age and sex, length of follow-up, IOL model, IOL power, neodymium:YAG laser capsulotomy, corrected distance visual acuity (CDVA), spherical equivalent (SE), and selected ocular and systemic diseases and medications.

Results

Glistenings occurred in 157 (60.4%) of the 260 eyes; they were absent in 103 eyes (39.6%). Glistenings were of grade 1 severity in 87 eyes (33.5%) and of grade 2 severity in 70 eyes (26.9%).

Conclusions

The results suggest a potential association between the incidence of glistenings and IOL power and glaucoma, but not between glistenings and age, sex, IOL model, length of follow-up, CDVA, SE, or most ocular and systemic diseases and medications.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Neither author has a financial or proprietary interest in any material or method mentioned.

 Supported by Alcon, Inc., Fort Worth, Texas, USA.

PII: S0886-3350(09)00782-2

doi:10.1016/j.jcrs.2009.06.029

Journal of Cataract & Refractive Surgery
Volume 35, Issue 12 , Pages 2121-2126, December 2009

Article Tools

* Image Usage & Resolution